An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available

Trial Profile

An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions; Expanded access
  • Sponsors Novartis; Novartis Pharma A.G.
  • Most Recent Events

    • 21 Mar 2018 Status changed from recruiting to completed.
    • 12 Jan 2018 This trial has been completed in Bulgaria.
    • 12 Dec 2017 Safety and efficacy results (n=75; data cutoff: Jan 15, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top